© 1997 American Heart Association, Inc.
Articles |
Platelet Integrin 
IIbß3 (GPIIb-IIIa) Is Not Implicated in the Binding of LDL to Intact Resting Platelets
the Department of Biochemistry (J.P., R.F., A.B., M.A.E.), Hospital Universitario Son Dureta, Palma de Mallorca, Spain, and the Department of Atherothrombosis and Vascular Biology (C.C., C. de C.), Institut de Recerca del Hospital Santa Creu i Sant Pau, Barcelona, Spain.
Correspondence to Javier Pedreno MD, PhD, Fundacio d'Investigacio Cardiovascular (Pabellon Cardiologia) Hospital de la Santa Creu i Sant Pau, Avenida San Antonio Maria Claret 167, 08025 Barcelona, Spain.
It has been suggested that the fibrinogen receptor (glycoprotein [GP] IIb-IIIa or platelet integrin IIbß3) could be the binding site for low-density lipoprotein (LDL); however, recent data do not support this. Furthermore, GPIIb and not the GPIIb-IIIa complex is the main binding protein for lipoprotein(a) [Lp(a)]. In the present study, we have investigated the interaction between Lp(a) particles and platelet LDL binding sites and whether platelet integrin IIbß3 is implicated. Displacement experiments showed that 125I-LDL binding to intact resting platelets was inhibited with the same apparent affinity by both unlabeled LDL and apolipoprotein(a)-free lipoprotein particles [Lp(a)-, an LDL-like particle prepared from Lp(a)]. Hill coefficients for displacement curves suggested that a single set of binding sites was involved. In contrast, both native and oxidized Lp(a) particles were unable to inhibit platelet LDL binding. Furthermore, platelets bound 125I-Lp(a)- particles to a class of saturable binding sites numbering approximately 1958±235 binding sites per platelet with a dissociation constant (Kd) of 48.3±12x10-9 mol/L. These values were similar to those obtained for LDL. In contrast to Lp(a), evidence indicates that platelet integrin IIbß3 was not involved in the interaction of LDL and intact resting platelets. First, specific ligands for platelet integrin IIbß3, such as fibrinogen, vitronectin, and fibronectin, were unable to inhibit the binding of LDL to intact resting platelets. Second, similar LDL binding characteristics (Kd and Bmax values) were found in platelets from control subjects and patients with type I and type II Glanzmann's thrombasthenia, characterized by total and partial lack of GPIIb-IIIa and fibrinogen, respectively. Third, polyclonal antibodies against the GPIIb-IIIa complex (edu-3 and 5B12), human antiserums against platelet alloantigens (anti-Baka/B and anti-PLA1/2), anti-integrin subunits (anti-v and anti-ß3), and a wide panel of monoclonal antibodies (mAbs) against well-known epitopes of GPIIb (M3, M4, M5, M6, and M95-2b) and GPIIIa (P23-7, P33, P37, P40, and P97) did not affect platelet LDL binding. Finally, in contrast to the proaggregatory effect of native and oxidized LDL, both native and oxidized Lp(a) particles caused a significant dose-dependent decrease of collagen-induced platelet aggregation. In conclusion, we demonstrate that neither the GPIIb-IIIa complex nor GPIIb and GPIIIa individually are membrane binding proteins for LDL on intact resting platelets. Lp(a) particles do not interact with platelet LDL binding sites, and their biological response is clearly different from that of LDL.
Key Words: binding sites • lipoprotein(a) • platelet integrin IIbß3 • oxidized lipoproteins
This article has been cited by other articles:
 |
|
 |
|
  S. Tetik, F. Uras, E. Eksioglu-Demiralp, and K. Turay Yardimci Low-Density Lipoprotein Specifically Binds Glycoprotein IIb/IIIa: A Flow Cytometric Method for Ligand-Receptor Interaction Clinical and Applied Thrombosis/Hemostasis, April 1, 2008; 14(2): 210 - 219. [Abstract] [PDF]
|
|
|
|
 |
|
 S. J. A. Korporaal, I. A. M. Relou, M. van Eck, V. Strasser, M. Bezemer, G. Gorter, T. J. C. van Berkel, J. Nimpf, J.-W. N. Akkerman, and P. J. Lenting Binding of Low Density Lipoprotein to Platelet Apolipoprotein E Receptor 2' Results in Phosphorylation of p38MAPK J. Biol. Chem., December 10, 2004; 279(50): 52526 - 52534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nomura, A. Shouzu, S. Omoto, M. Nishikawa, T. Iwasaka, and S. Fukuhara Activated Platelet and Oxidized LDL Induce Endothelial Membrane Vesiculation: Clinical Significance of Endothelial Cell-Derived Microparticles in Patients With Type 2 Diabetes Clinical and Applied Thrombosis/Hemostasis, July 1, 2004; 10(3): 205 - 215. [Abstract] [PDF]
|
|
|
|
 |
|
 L. D Tsironis, J. V Mitsios, H. J Milionis, M. Elisaf, and A. D Tselepis Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: role of apolipoprotein (a) and endogenous PAF-acetylhydrolase Cardiovasc Res, July 1, 2004; 63(1): 130 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Hackeng, M. Huigsloot, M. W. Pladet, H. K. Nieuwenhuis, H. J. M. van Rijn, and J.-W. N. Akkerman Low-Density Lipoprotein Enhances Platelet Secretion Via Integrin-{alpha}IIbß3–Mediated Signaling Arterioscler Thromb Vasc Biol, February 1, 1999; 19(2): 239 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Rand, W. Sangrar, M. A. Hancock, D. M. Taylor, S. M. Marcovina, M. A. Packham, and M. L. Koschinsky Apolipoprotein(a) Enhances Platelet Responses to the Thrombin Receptor–Activating Peptide SFLLRN Arterioscler Thromb Vasc Biol, September 1, 1998; 18(9): 1393 - 1399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Maschberger, M. Bauer, J. Baumann-Siemons, K. J. Zangl, E. V. Negrescu, A. J. Reininger, and W. Siess Mildly Oxidized Low Density Lipoprotein Rapidly Stimulates via Activation of the Lysophosphatidic Acid Receptor Src Family and Syk Tyrosine Kinases and Ca2+ Influx in Human Platelets J. Biol. Chem., June 16, 2000; 275(25): 19159 - 19166. [Abstract] [Full Text] [PDF]
|
|